Literature DB >> 2894558

Epidemic yellow fever in eastern Nigeria, 1986.

K M De Cock1, T P Monath, A Nasidi, P M Tukei, J Enriquez, P Lichfield, R B Craven, A Fabiyi, B C Okafor, C Ravaonjanahary.   

Abstract

An epidemic of yellow fever occurred in the eastern part of Nigeria during the second half of 1986. Oju, in Benue State, was the most heavily affected region, but yellow fever also occurred in surrounding areas, particularly Ogoja, in Cross River State. In Oju, the mean attack and mortality rates were 4.9% and 2.8%, respectively. Sex and age specific rates were highest in males and in the 20-29 yr age group. The overall case fatality rate was approximately 50%. Diagnosis was confirmed by IgM capture enzyme-linked immunosorbent assay (ELISA) and complement fixation (CF) tests. Entomological investigations implicated Aedes africanus as the epidemic vector. Oju alone probably had about 9800 cases of yellow fever with jaundice, and some 5600 deaths. Outbreaks of this nature could be prevented by inclusion of yellow fever in the Expanded Programme on Immunisation, in areas subject to recurrent epidemics.

Entities:  

Mesh:

Year:  1988        PMID: 2894558     DOI: 10.1016/s0140-6736(88)91425-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  10 in total

Review 1.  Primary prevention and international travel: infections, immunizations, and antimicrobial prophylaxis.

Authors:  G S Ferenchick; D H Havlichek
Journal:  J Gen Intern Med       Date:  1989 May-Jun       Impact factor: 5.128

2.  The whole iceberg: estimating the incidence of yellow fever virus infection from the number of severe cases.

Authors:  Michael A Johansson; Pedro F C Vasconcelos; J Erin Staples
Journal:  Trans R Soc Trop Med Hyg       Date:  2014-06-30       Impact factor: 2.184

3.  Yellow fever in west Africa: a retrospective glance.

Authors:  J S Porterfield
Journal:  BMJ       Date:  1989 Dec 23-30

4.  Nucleotide sequence variation of the envelope protein gene identifies two distinct genotypes of yellow fever virus.

Authors:  G J Chang; B C Cropp; R M Kinney; D W Trent; D J Gubler
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

5.  Does restricted distribution limit access and coverage of yellow fever vaccine in the United States?

Authors:  T P Monath; J A Giesberg; E G Fierros
Journal:  Emerg Infect Dis       Date:  1998 Oct-Dec       Impact factor: 6.883

6.  The Nigeria Centre for Disease Control.

Authors:  Ahmad Muhammad Njidda; Oyeronke Oyebanji; Joshua Obasanya; Olubunmi Ojo; Adebayo Adedeji; Nwando Mba; John Oladejo; Chikwe Ihekweazu
Journal:  BMJ Glob Health       Date:  2018-04-17

7.  Fifty-five years of international epidemic-assistance investigations conducted by CDC's disease detectives.

Authors:  Italia V Rolle; Michele L Pearson; Peter Nsubuga
Journal:  Am J Epidemiol       Date:  2011-12-01       Impact factor: 4.897

8.  The resurgence of yellow fever outbreaks in Nigeria: a 2-year review 2017-2019.

Authors:  Terna Nomhwange; Anne Eudes Jean Baptiste; Obi Ezebilo; Joseph Oteri; Lois Olajide; Kizito Emelife; Shehu Hassan; Erdoo R Nomhwange; Kennedy Adejoh; Faith Ireye; Eyo E Nora; Adamu Ningi; Blaise Bathondeli; Oyewale Tomori
Journal:  BMC Infect Dis       Date:  2021-10-11       Impact factor: 3.090

9.  Yellow Fever in Africa: estimating the burden of disease and impact of mass vaccination from outbreak and serological data.

Authors:  Tini Garske; Maria D Van Kerkhove; Sergio Yactayo; Olivier Ronveaux; Rosamund F Lewis; J Erin Staples; William Perea; Neil M Ferguson
Journal:  PLoS Med       Date:  2014-05-06       Impact factor: 11.069

10.  Modelling the large-scale yellow fever outbreak in Luanda, Angola, and the impact of vaccination.

Authors:  Shi Zhao; Lewi Stone; Daozhou Gao; Daihai He
Journal:  PLoS Negl Trop Dis       Date:  2018-01-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.